Home » Posts tagged 'Kiran Mazumdar-Shaw'
Tag Archives: Kiran Mazumdar-Shaw
Kiran Mazumdar Shaw Conferred with ‘The Global Leadership in Engineering 2016’ Award by USC
.

http://societyofwomenengineers.swe.org/awards/individual-awards/4153-global-leadership

The Global Leadership Award honors a person with at least fifteen (15) years professional experience who has worked in and led an internationally based engineering, scientific or technology-based business or organization, and in doing so, serves as a role model to women engineers and technologists worldwide. A maximum of three (3) awards may be presented annually.
“This award is a recognition of Biocon’s significant role in harnessing the potential of Biotechnology to provide affordable access to highly complex bio-pharmaceuticals like Insulins and monoclonal antibodies for the benefit of patients the world over.” – Kiran Mazumdar-Shaw

//////Kiran Mazumdar Shaw, ‘The Global Leadership in Engineering 2016’ , Award by USC
Biocon’s Rosuvastatin Calcium tablets get EU approval to treat hyperlipidemia

Biocon’s Rosuvastatin Calcium tablets get EU approval to treat hyperlipidemia
Indian biopharmaceutical company Biocon has received approval from the European Commission for its Rosuvastatin Calcium tablets to treat hyperlipidemia or mixed dyslipidemia.

Indian biopharmaceutical company Biocon has received approval from the European Commission for its Rosuvastatin Calcium tablets to treat hyperlipidemia or mixed dyslipidemia.
Hyperlipidemia is a common genetic disorder that increases lipids and/or lipoproteins levels in the blood.
The first generic formulation approval will allow Biocon to sell Rosuvastatin Calcium 5mg, 10mg, 20mg and 40mg tablets in more than 15 European countries, starting in fiscal 2017.
The company plans to collaborate with regional partners to market the drug; a generic equivalent of Crestor tablets.
Biocon chairperson and managing director Kiran Mazumdar-Shaw said: “This is indeed a proud moment for Biocon’s Small Molecules business.
Biocon chairperson and managing director Kiran Mazumdar-Shaw
“This approval paves the way for Biocon to launch Rosuvastatin Calcium tablets in several European countries.”
The approval will allow the company to address the $1.2bn opportunity in the EU. It will also make it easier for the company to market its products in emerging markets, where regulatory clearances are primarily based on approvals given by regulators in the US / EU.
Biocon was the first generic company to receive a certificate of suitability (CEP) for Rosuvastatin Calcium API from the European Directorate for the Quality of Medicines (EDQM).
CEP certification indicates that an API is suitable for use in medicinal products in the EU.
Biocon CEO and joint managing director Dr Arun Chandavarkar said: “The European approval for Biocon’s generic version of Rosuvastatin Calcium underscores Biocon’s unique strengths in the chronic therapies space and our compliance with global standards that enable us to achieve the highest quality standards for all our products.
“It augurs well for this nascent business, which will be one of our growth drivers in the coming years.”
The company plans to boost its generic formulations business with a target of 20-25 filings over the next few years.
Additionally, Biocon is developing a new facility in Bengaluru, in the Indian state of Karnataka, where it will produce oral solid dosage formulations.
Biocon CEO and joint managing director Dr Arun Chandavarkar
/////////
Biocon chief Kiran Mazumdar-Shaw receives Kiel Institute’s ‘2014 Global Economy Prize’
![]()
The award, established in 2005 by the Kiel Institute, is bestowed upon individuals who have been pioneers in finding solutions to global economic problems.
BANGALORE: Biotech major Biocon today said its Chairperson and Managing Director Kiran Mazumdar-Shaw has been awarded the Kiel Institute’s most coveted ‘2014 Global Economy Prize’ for Business.
She was honoured at the institute’s 100th anniversary celebrations at Kiel in Germany.
The award, established in 2005 by the Kiel Institute, is bestowed upon individuals who have been pioneers in finding solutions to global economic problems by strongly influencing and implementing eco ..

With Prof. Thaler and President Sirleaf — in Kiel, Germany.
http://economictimes.indiatimes.com/articleshow/37076858.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst

Signing the register at the Kiel Institute for the World Economy. — in Kiel, Germany.

With Lord Mayor of Kiel and President Dennis Snower of Kiel Institute. — in Kiel, Germany.

Signed register at the Kiel Institute. — in Kiel, Germany.
Small molecule, API biz to be growth drivers for company: Kiran Mazumdar Shaw, Biocon
“We have focused on creating key growth drivers and have structured the company along those growth drivers,” says Kiran Mazumdar Shaw. (BCCL)…………. owner BIOCON
MY, DR AMC COMMENTS- BIOCON GREAT PERFORMANCE, U ARE EVERYWHERE
Kiran Mazumdar Shaw: We have focused on creating key growth drivers and have structured the company along those growth drivers. These growth drivers are beginning to deliver very strongly for us.
The first is our small molecule business vertical, which is about our historic statins and immunosuppressant’s API business. This particular vertical going forward is envisioned to go up the value chain along an ANDA path and we believe that will improve the quality of earnings in this particular vertical, which for a long time was under pressure because of commoditisation of statins.http://economictimes.indiatimes.com/opinion/interviews/small-molecule-api-biz-to-be-growth-drivers-for-company-kiran-mazumdar-shaw-biocon/articleshow/21975113.cms
Need For A Smarter Regulatory System To Ensure Access To Affordable Biologics: The Biosimilars

Indian Pharma Market Needs Strong Regulatory Set-up: Kiran Mazumdar-Shaw
Kiran Mazumdar-Shaw, MD, BIOCON
Indian Pharma Market Needs Strong Regulatory Set-up: Kiran Mazumdar-Shaw, MD, BIOCON
Biocon is looking at gaining market share and improving its margins with a greater focus on its product mixes and organizational efficiencies. Biocon Chairman and Managing Director Kiran Mazumdar-Shaw tells Financial Express that the company has outpaced the market, despite various challenges and that the pharmaceutical market needs to have a more robust regulatory set-up. Edited excerpts:
READ ALL AT
http://kiranmazumdarshaw.blogspot.in/2013/07/indian-pharma-market-needs-strong.html
………………
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....












